PE20232046A1 - N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas - Google Patents
N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidasInfo
- Publication number
- PE20232046A1 PE20232046A1 PE2023001909A PE2023001909A PE20232046A1 PE 20232046 A1 PE20232046 A1 PE 20232046A1 PE 2023001909 A PE2023001909 A PE 2023001909A PE 2023001909 A PE2023001909 A PE 2023001909A PE 20232046 A1 PE20232046 A1 PE 20232046A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- alkyl
- group
- compounds
- cyanothiazolidin
- Prior art date
Links
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- XDSJWOOECLXJRL-MRXNPFEDSA-N N-[2-[(4R)-4-cyano-1,3-thiazolidin-3-yl]-2-oxoethyl]-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)quinoline-4-carboxamide Chemical compound N#C[C@H](CSC1)N1C(CNC(C(C1=C2)=CC=NC1=CC=C2C1=CN=C2N1CCCC2)=O)=O XDSJWOOECLXJRL-MRXNPFEDSA-N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 abstract 1
- 101710178372 Prolyl endopeptidase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- -1 compounds N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides Chemical class 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Abstract
Referido a compuestos N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas de Formula I, o una sal farmaceuticamente aceptable del mismo, en donde: X1 se selecciona entre el grupo que consiste en -S-, -S(O)- y -S(O)2-; R1 es H, halogeno, hidroxi, alquilo C1-3 o alcoxi C1-6; R2 se selecciona entre el grupo que consiste en: heterociclilo que contiene un total de 4 a 10 atomos en el anillo, heterociclilo que contiene un total de 5 a 10 atomos en el anillo, espiro heterociclilo que contiene un total de 6 a 11 atomos en el anillo, entre otros; R3 se selecciona entre el grupo que consiste en hidrogeno, halogeno y alquilo C1-3; R4 es H, halogeno y alquilo C1-3; R5 se selecciona entre el grupo que consiste en H, halogeno y alquilo C1-3; y R6 se selecciona entre el grupo que consiste en H, halogeno y alquilo C1-3. Estos compuestos regulan por la proteina de activacion de fibroblastos prolil endopeptidasa (FAP). Un compuesto seleccionado es (R)-N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-6-(5,6,7,8-tetrahidroimidazo[1,2-a]piridin-3-il)quinolin-4-carboxamida (Ejemplo 175) o una sal farmaceuticamente aceptable de la misma. Tambien se refiere a metodos para preparar dichos compuestos, compuestos intermedios, composiciones farmaceuticas que comprenden dichos compuestos, y su uso en el tratamiento de enfermedades hepaticas como esteatohepatitis no alcoholica (NASH), higado graso no alcoholico, entre otros.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063126593P | 2020-12-17 | 2020-12-17 | |
PCT/IB2021/061839 WO2022130270A1 (en) | 2020-12-17 | 2021-12-16 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20232046A1 true PE20232046A1 (es) | 2023-12-27 |
Family
ID=79164845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001909A PE20232046A1 (es) | 2020-12-17 | 2021-12-16 | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas |
Country Status (19)
Country | Link |
---|---|
US (2) | US20240101549A1 (es) |
EP (1) | EP4263535A1 (es) |
JP (1) | JP2023554405A (es) |
KR (1) | KR20230122080A (es) |
CN (1) | CN116745291A (es) |
AR (1) | AR124379A1 (es) |
AU (1) | AU2021403827A1 (es) |
CA (1) | CA3204318A1 (es) |
CL (1) | CL2023001763A1 (es) |
CO (1) | CO2023008921A2 (es) |
CR (1) | CR20230314A (es) |
DO (1) | DOP2023000124A (es) |
EC (1) | ECSP23053033A (es) |
IL (1) | IL303655A (es) |
MX (1) | MX2023007287A (es) |
PE (1) | PE20232046A1 (es) |
TW (1) | TW202239407A (es) |
UY (1) | UY39569A (es) |
WO (1) | WO2022130270A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202239407A (zh) | 2020-12-17 | 2022-10-16 | 瑞典商阿斯特捷利康公司 | N-(2-(4-氰基四氫噻唑-3-基)-2-側氧基乙基)-喹啉-4-甲醯胺 |
WO2023247489A1 (en) * | 2022-06-21 | 2023-12-28 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
WO2023247487A1 (en) * | 2022-06-21 | 2023-12-28 | Astrazeneca Ab | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW521072B (en) | 1997-06-02 | 2003-02-21 | Meiji Seika Kaisha | 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture |
FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
NZ524618A (en) | 2000-08-10 | 2004-08-27 | Mitsubishi Pharma Corp | Proline derivatives and use thereof as drugs |
JP2003026698A (ja) | 2000-09-27 | 2003-01-29 | Tokyo Inst Of Technol | 新規化合物、固定化物及び蛋白質のスクリーニング方法 |
GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
KR100998796B1 (ko) | 2003-01-31 | 2010-12-06 | 가부시키가이샤산와카가쿠켄큐쇼 | 디펩티딜 펩티다아제 iv를 저해하는 화합물 |
DK2210607T3 (da) * | 2003-09-26 | 2011-12-12 | Exelixis Inc | N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft |
WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
TWI366438B (en) | 2004-08-12 | 2012-06-21 | Ishihara Sangyo Kaisha | Fungicidal composition containing acid amide derivative |
EP1917001A2 (en) | 2005-08-11 | 2008-05-07 | F.Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
EP2099778A2 (en) | 2006-11-21 | 2009-09-16 | Smithkline Beecham Corporation | Amido anti-viral compounds |
AU2011225095C1 (en) | 2010-03-11 | 2017-01-19 | Sumitomo Dainippon Pharma Co., Ltd. | N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
CN108383893A (zh) | 2011-08-30 | 2018-08-10 | 塔夫茨大学信托人 | 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂 |
UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
US9346814B2 (en) | 2012-01-17 | 2016-05-24 | Universiteit Antwerp | FAP inhibitors |
US9630958B2 (en) | 2012-07-23 | 2017-04-25 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
EP3122747B1 (en) | 2014-03-28 | 2020-05-20 | North & South Brother Pharmacy Investment Company Limited | Dihydropyrimidine compounds and their application in pharmaceuticals |
BR112016024414A2 (pt) | 2014-04-22 | 2017-08-15 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
SG10201901192TA (en) | 2014-09-10 | 2019-03-28 | Epizyme Inc | Smyd inhibitors |
WO2017189569A1 (en) | 2016-04-25 | 2017-11-02 | Trustees Of Tufts College | Multimediator dpp4 and fap inhibitors, and uses related thereto |
US10899758B2 (en) | 2016-09-16 | 2021-01-26 | Vitae Pharmaceuticals, Llc | Inhibitors of the menin-MLL interaction |
WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
CN108690043B (zh) | 2017-04-11 | 2019-10-18 | 东莞东阳光科研发有限公司 | 喹啉类衍生物及其制备方法和用途 |
BR112019021899A2 (pt) | 2017-04-20 | 2020-08-18 | The Regents Of The University Of California | moduladores de k-ras |
US11584744B2 (en) | 2017-06-23 | 2023-02-21 | University Of Washington | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them |
AU2018312836B2 (en) | 2017-08-07 | 2022-12-08 | Joint Stock Company "Biocad" | Novel heterocyclic compounds as CDK8/19 inhibitors |
WO2019084271A1 (en) | 2017-10-25 | 2019-05-02 | Children's Medical Center Corporation | PAPD5 INHIBITORS AND METHODS OF USE |
AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
JP2021506862A (ja) | 2017-12-19 | 2021-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Tlr7/8アンタゴニストおよびそれらの使用 |
EP3749663A1 (en) | 2018-02-06 | 2020-12-16 | Universität Heidelberg | Fap inhibitor |
KR20210040085A (ko) | 2018-07-31 | 2021-04-12 | 메르크 파텐트 게엠베하 | Tlr7/8 안타고니스트 및 이의 용도 |
CN112771055B (zh) | 2018-08-08 | 2023-10-20 | 住友制药株式会社 | 光学活性桥接哌啶衍生物 |
WO2020045334A1 (ja) | 2018-08-27 | 2020-03-05 | 大日本住友製薬株式会社 | 光学活性なアザビシクロ環誘導体 |
US10815241B2 (en) | 2018-08-27 | 2020-10-27 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active azabicyclo ring derivative |
CN113811529A (zh) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | 成纤维细胞激活蛋白抑制剂 |
US20220380365A1 (en) | 2019-09-27 | 2022-12-01 | Sumitomo Dainippon Pharma Co., Ltd. | Crosslinked optically active secondary amine derivative |
TW202132281A (zh) | 2019-11-06 | 2021-09-01 | 南韓商柳韓洋行股份有限公司 | 吡咯啶及哌啶類化合物 |
TW202239407A (zh) | 2020-12-17 | 2022-10-16 | 瑞典商阿斯特捷利康公司 | N-(2-(4-氰基四氫噻唑-3-基)-2-側氧基乙基)-喹啉-4-甲醯胺 |
-
2021
- 2021-12-16 TW TW110147244A patent/TW202239407A/zh unknown
- 2021-12-16 AU AU2021403827A patent/AU2021403827A1/en active Pending
- 2021-12-16 PE PE2023001909A patent/PE20232046A1/es unknown
- 2021-12-16 UY UY0001039569A patent/UY39569A/es unknown
- 2021-12-16 CR CR20230314A patent/CR20230314A/es unknown
- 2021-12-16 KR KR1020237023914A patent/KR20230122080A/ko unknown
- 2021-12-16 MX MX2023007287A patent/MX2023007287A/es unknown
- 2021-12-16 JP JP2023536454A patent/JP2023554405A/ja active Pending
- 2021-12-16 CA CA3204318A patent/CA3204318A1/en active Pending
- 2021-12-16 US US18/257,123 patent/US20240101549A1/en active Pending
- 2021-12-16 IL IL303655A patent/IL303655A/en unknown
- 2021-12-16 CN CN202180084189.5A patent/CN116745291A/zh active Pending
- 2021-12-16 WO PCT/IB2021/061839 patent/WO2022130270A1/en active Application Filing
- 2021-12-16 EP EP21834914.0A patent/EP4263535A1/en active Pending
- 2021-12-16 AR ARP210103519A patent/AR124379A1/es unknown
-
2023
- 2023-06-12 US US18/332,897 patent/US11858924B2/en active Active
- 2023-06-14 DO DO2023000124A patent/DOP2023000124A/es unknown
- 2023-06-15 CL CL2023001763A patent/CL2023001763A1/es unknown
- 2023-07-05 CO CONC2023/0008921A patent/CO2023008921A2/es unknown
- 2023-07-14 EC ECSENADI202353033A patent/ECSP23053033A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2023008921A2 (es) | 2023-07-21 |
CN116745291A (zh) | 2023-09-12 |
CA3204318A1 (en) | 2022-06-23 |
TW202239407A (zh) | 2022-10-16 |
AR124379A1 (es) | 2023-03-22 |
US20230312550A1 (en) | 2023-10-05 |
UY39569A (es) | 2022-07-29 |
MX2023007287A (es) | 2023-07-03 |
JP2023554405A (ja) | 2023-12-27 |
CR20230314A (es) | 2023-08-18 |
DOP2023000124A (es) | 2023-07-09 |
AU2021403827A1 (en) | 2023-07-27 |
IL303655A (en) | 2023-08-01 |
EP4263535A1 (en) | 2023-10-25 |
US11858924B2 (en) | 2024-01-02 |
US20240101549A1 (en) | 2024-03-28 |
ECSP23053033A (es) | 2023-08-31 |
WO2022130270A1 (en) | 2022-06-23 |
CL2023001763A1 (es) | 2023-11-17 |
KR20230122080A (ko) | 2023-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20232046A1 (es) | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas | |
PE20230161A1 (es) | Inhibidores de proteinas kras mutantes | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
PE20211411A1 (es) | Compuestos de anillo fusionado | |
MA50065B1 (fr) | Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53 | |
EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
EA200401194A1 (ru) | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение | |
AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
AR036103A1 (es) | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento | |
UY29301A1 (es) | Derivados amida | |
ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
AR050617A1 (es) | Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas | |
AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
AR044006A1 (es) | Compuesto de fenilpiperidinilo, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
DE602005027677D1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung | |
AR040580A1 (es) | Derivados de pirazol heterobiciclico como inhibidores de la quinasa | |
EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА |